No Data
No Data
No Data
No Data
No Data
Express News | Acadia Pharmaceuticals Announces Trofinetide New Drug Submission For Treatment Of Rett Syndrome Accepted For Filing And Priority Review By Health Canada
Moomoo 24/7Apr 22 09:06 ET
Express News | ACADIA Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Moomoo 24/7Apr 22 09:04 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock
BusinesswireApr 19 16:05 ET
Express News | ACADIA Pharmaceuticals Inc : Needham Cuts Target Price to $30 From $32: Needham Cuts Target Price to $30 From $32
Moomoo 24/7Apr 19 05:35 ET
Acadia Pharmaceuticals Presents New DAYBUE Clinical Data At The 2024 American Academy Of Neurology Annual Meeting
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that two oral presentations featuring DAYBUE (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (A
BenzingaApr 17 16:19 ET
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
26 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table provides
BenzingaApr 10 16:01 ET
Jaguar8 : Again.
TrytosaveabitOP Jaguar8: Yup! Another that’s probably going to plummet?
Jaguar8 TrytosaveabitOP: Big time plummet. I hope nobody is left bagholding
TrytosaveabitOP Jaguar8: You and me both! Even if it has a great pipeline with others soon to be reported! These are dangerous plays for just that reason! Some are just a huge overreaction! Some are not though.
Jaguar8 TrytosaveabitOP: It’s like NERV
No Data
No Data